TABLE 2.

Demographic information on patients treated with anti-CGRP mAbs.

	Total		Erenumab		Galcanezumab		Fremanezumab		Eptinezumab
	(n = 65,792)		(n = 38,515)		(n = 19,485)		(n = 5,332)		(n = 2,460)
	n	%	n	%	n	%	n	%	n	%
Sex
Male	7,646	11.62	4,736	12.30	2,124	10.90	493	9.25	293	11.91
Female	47,431	72.09	26,365	68.45	14,860	76.26	4,362	81.81	1,844	74.96
Unknown	10,715	16.29	7,414	19.25	2,501	12.84	477	8.95	323	13.13
Age (years)
<18	278	0.38	202	0.52	43	0.22	29	0.54	4	0.16
18–45	12,163	11.91	7,909	20.53	2,597	13.33	1,000	18.75	657	26.71
45–65	15,456	24.58	10,689	27.75	2,643	13.56	1,112	20.86	1,012	41.14
>65	5,343	6.52	4,067	10.56	632	2.25	383	7.18	261	9.44
Unknown	32,552	56.61	15,648	40.63	13,570	69.64	2,808	52.66	526	21.38
Mean (SD)	48.66 (14.96)		49.84 (15.18)		46.32 (14.42)		48.19 (15.04)		49.59 (13.83)
Reporting year
2018	7,427	11.29	7,088	18.40	218	1.12	121	2.27	0	0
2019	16,444	24.99	10,716	27.82	4,499	23.09	1,229	23.05	0	0
2020	15,783	23.99	8,439	21.91	6,351	32.59	869	16.30	124	5.04
2021	12,131	18.44	5,629	14.62	4,408	22.62	1,359	25.49	735	29.88
2022	11,240	17.08	5,335	13.85	3,305	16.96	1,387	26.01	1,213	49.31
2023	2,767	4.21	1,308	3.40	704	3.61	367	6.88	388	15.77
Serious outcomes
Hospitalization	1,264	2.86	1,271	3.30	456	2.34	289	5.42	67	2.72
Disability	348	0.79	515	1.34	160	0.82	98	1.84	7	0.28
Life-threatening	175	0.40	209	0.54	42	0.22	32	0.60	6	0.24
Death	252	0.57	296	0.77	40	0.21	35	0.66	9	0.37
Reported from the United States	62,721	95.33	36,436	94.60	19,151	98.29	4,703	88.20	2,431	98.82